 Home > Active Ingredient News > Blood System > J Clin Oncol: Efficacy and safety of nasoprilumab in the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy

J Clin Oncol: Efficacy and safety of nasoprilumab in the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy

 Last Update: 2022-05-21
 Source: Internet
 Author: User

Tags

stem cells journal

javascript open source

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a serious complication of hematopoietic stem cell transplantation with a high mortality rate and no approved treatment

Nasoplimab (OMS721) is a mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor developed for the treatment of HSCT-TMA

This study is a single-arm, open-label, flight trial to evaluate the safety and efficacy of nasoprilumab in adult patients with HSCT-TMA

A single-arm, open-label flight trial to evaluate the safety and efficacy of nasoprilumab in adult patients with HSCT-TMA

Patients were recruited with any of the following three TMAs: atypical hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, or HSCT-TMA

A total of 28 patients were recruited and received at least one dose of nasoprilumab (Master Analysis Set [FAS])

The overall response rate was 61% The overall response rate was 61%

74% of the total population achieved organ function improvement 74% of the total population achieved organ function improvement

Nasoprilumab has good safety in patients with HSCT-TMA, and can significantly improve the remission rate and prolong overall survival

Original source:

Original Source: Original Source:

Samer K.

Samer K.
Khaled, et al.
Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy.
Journal of Clinical Oncology.
April 20, 2022.
https: //ascopubs.
org/doi/full/10.
1200/JCO.
21.
02389

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.